Iksuda Therapeutics, a Newcastle UK-based company focused on developing antibody drug conjugates (ADCs), raised $47M in funding.
The round was co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners.
The company intends to use the funds to accelerate clinical progression of its pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need.
Led by Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics is the developer of a new generation of antibody drug conjugates (ADCs). Its ADC programmes target tumours that currently have limited treatment options and high relapse rates. Its lead pre-clinical candidate, IKS03, is a CD19-targeted ADC candidate for B-cell cancers.
The investment will enable progression of IKS03 to first-in-human phase 1 clinical trials and accelerate earlier-stage programs including IKS04 and IKS012 to IND filing.